1. Monkeypox virus induces the synthesis of less dsRNA than vaccinia virus, and is more resistant to the anti-poxvirus drug, IBT, than vaccinia virus
- Author
-
Heather Harrington, Samantha Cotsmire, Karen V. Kibler, Jeffrey Langland, Stacy D. White, Jeffrey Liao, Brian Patrick Johnson, William D. Arndt, Bertram L. Jacobs, and Trung Huynh
- Subjects
0301 basic medicine ,Transcription, Genetic ,viruses ,Virulence ,Vaccinia virus ,Biology ,Virus Replication ,Antiviral Agents ,Virus ,Article ,Microbiology ,Cell Line ,03 medical and health sciences ,chemistry.chemical_compound ,Open Reading Frames ,Viral Proteins ,Virology ,Drug Resistance, Viral ,Humans ,Monkeypox virus ,RNA, Double-Stranded ,virus diseases ,biology.organism_classification ,Protein kinase R ,3. Good health ,RNA silencing ,030104 developmental biology ,chemistry ,Viral replication ,Cell culture ,DNA, Viral ,Vaccinia ,HeLa Cells - Abstract
Monkeypox virus (MPXV) infection fails to activate the host anti-viral protein, PKR, despite lacking a full-length homologue of the vaccinia virus (VACV) PKR inhibitor, E3. Since PKR can be activated by dsRNA produced during a viral infection, we have analyzed the accumulation of dsRNA in MPXV-infected cells. MPXV infection led to less accumulation of dsRNA than VACV infection. Because in VACV infections accumulation of abnormally low amounts of dsRNA is associated with mutations that lead to resistance to the anti-poxvirus drug isatin beta-thiosemicarbazone (IBT), we investigated the effects of treatment of MPXV-infected cells with IBT. MPXV infection was eight-fold more resistant to IBT than wild-type vaccinia virus (wtVACV). These results demonstrate that MPXV infection leads to the accumulation of less dsRNA than wtVACV, which in turn likely leads to a decreased capacity for activation of the dsRNA-dependent host enzyme, PKR.
- Published
- 2016